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Neuroendocrine tumors (NETs) have a high predilection for metastasizing to the liver and can cause severe debilitating symptoms
adversely aﬀecting quality of life. Although surgery remains the treatment of choice, many liver metastases are inoperable at
presentation. Hepatic arterial embolization procedures take advantage of the arterial supply of NET metastases. The goals of
these therapies are twofold: to increase overall survival by stabilizing tumor growth, and to reduce the morbidity in symptomatic
patients. Patients treated with hepatic arterial embolization demonstrate longer progression-free survival and have 5-year survival
rates of nearly 30%. The safety of repeat embolizations has also been proven in the setting of recurrent symptoms or progression of
the disease. Despite not being curative, hepatic arterial embolization should be used in the management of NETs with liver metas-
tases. Long-term survival is not uncommon, making aggressive palliation of symptoms an important component of treatment.
1.Introduction
Neuroendocrine tumors (NETs) consist of a heterogeneous
group of neoplasms of varying presentation and prognosis.
Whileacompletelistofthisfamilyoftumorsincludesdozens
of distinct histopathologic subtypes from multiple diﬀerent
organ systems, the majority of NETs are carcinoid tumors
of the gastrointestinal tract and endocrine tumors of the
pancreatic islet cells [1–3]. Primary liver NETs have been
reported but are unusual and will not be discussed in this
paper [4].
NETs are relatively rare, with an incidence ranging
from 2.5 to 5.3 per 100,000 [3, 5]. The prevalence is
signiﬁcantly higher at about 35 per 100,000, indicating that
many patients are alive with disease [3, 6]. However, these
ﬁgures may not capture the full burden of NET disease,
since conﬂicting nomenclature systems exist, making them
diﬃcult to classify and quantify [1, 3, 5–7]. Although some
NETs are more aggressive in their behavior than others,
all have the potential for distant metastases and should be
considered malignant. In patients with resectable tumors
without metastatic disease, surgery is considered the gold
standard and is the only curative option. 5-year survival rates
in patients with localized, nonmetastatic NETs undergoing
curative resection range from 80% to 100% [2, 6].
While many NETs are nonfunctioning, these tumors
are traditionally categorized by their classic patterns of
symptoms arising from the secretion of various peptides
and hormones [8]. For example, patients with gastrin
hypersecretion from a gastrinoma tumor may present with
severe peptic ulcer disease refractory to treatment. Insuli-
nomas can cause severe hypoglycemia, while glucagonomas
manifest with hyperglycemia and diabetes. Other NETs
includeVIPoma,characterizedbydiarrheaandhypokalemia,
and somatostatinoma, presenting with cholelithiasis, dia-
betes, and steatorrhea. Carcinoid tumors of the GI tract
frequently produce serotonin (5-HT), which can manifest
as skin ﬂushing, severe diarrhea, abdominal cramping, and
electrolyte abnormalities [8].
The symptoms associated with functional NETs may be
severe and debilitating and detract signiﬁcantly from the
quality of life of the patient; therefore, aggressive treatments
to reduce symptoms have an important role in therapy
[8]. Even in the setting of an unresectable primary tumor
or widely metastatic disease, most NETs have an indolent
course; 5–10-year survival with stage IV disease is not2 International Journal of Hepatology
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Figure 1: CT of bilobar hepatic metastases from a malignant NET in the (a) arterial phase and (b) venous phase. The characteristic
enhancement of the tumor on arterial phase is apparent, as well as the relative darkening of the tumor on venous phase; the area of central
necrosis is dark in both phases. Note the primary NET in the tail of the pancreas.
uncommon and makes the treatment of symptoms a funda-
mental component of patient care [3, 9–14].
2.Treatment ofMetastaticDisease
Because the majority of NETs arise from the gastrointestinal
tract and the pancreas, the liver is the most common site of
metastases [15]. In patients with liver metastases, 75–80%
will present with these metastases at the time of diagnosis
(synchronous), while 20–25% of patients develop liver
metastases during the course of treatment (metachronous)
[8]. An estimated 80–90% of patients with liver metastases
are inoperable at presentation [16]. Many primary NETs are
small in size, and it is not unusual for the liver metastases to
be of greater volume than the primary tumor. Given the high
tumor burden often associated with metastases, symptoms
can become signiﬁcantly worse as the disease advances. In
addition, many of the peptides and hormones produced
by NETs are eliminated by metabolism through the liver.
Therefore, it is only after liver metastases are present, and
these compounds spill directly into the systemic circulation,
that the phenotype of the tumor is fully expressed. As a
result, symptom control can become increasingly important
as metastases develop.
Surgical resection of hepatic metastases has been shown
to reduce symptoms and is indicated for this purpose alone
[2, 12]. In addition, some data indicate an improvement in
overall survival as well, and therefore metastasectomy should
be considered for resectable disease even in patients with
nonfunctional tumors [10, 12, 17]. Meaningful improve-
ments in symptom control and overall survival can be
achieved even if complete resection of metastatic disease is
not possible. However, available data suggest that debulking
should only be considered if greater than 90% of the tumor
burden can be resected [11, 18]. Two-step surgeries can be
considered to increase resectability in bilobar disease [19].
While resection is preferred, excessive tumor bulk, tumor
location, and other biological factors often preclude surgery.
Even with resection, recurrence is common (50–60% at 5
years) and repeat hepatectomy may not be feasible [20, 21].
In these cases where resection is not possible or would not
be tolerated by the patient’s physiology, interventional radi-
ology alternatives to surgery have been proposed, including
radiofrequency ablation, hepatic arterial radioembolization
with 90Y, and hepatic arterial bland or chemoembolization.
The goals of these therapies are twofold: to increase overall
survival by stabilizing tumor growth, and to reduce the
morbidity in symptomatic patients.
The radiologic appearance of liver metastases from NETs
is distinct and has important ramiﬁcations for treatment.
Compared to liver metastases that are of gastrointestinal
origin, metastases from NETs derive a greater amount of
their blood supply from the hepatic artery. As a result,
when imaged during the arterial phase, metastatic NETs
will typically appear brighter than the surrounding liver;
and during the venous phase when the normal liver
parenchyma is ﬁlled with contrast, NET metastases will
appear darker than the surrounding liver. In other words,
NET metastases typically “light up and wash out” (Figure 1)
[22]. This pattern of enhancement is similar to that seen
with hepatocellular carcinoma and is ideally suited for the
arterial embolization techniques more commonly associated
with that disease. Treatment response can be assessed using
radiographic measures by examining the degree of enhance-
ment of the lesions following embolization procedures
(Figure 2).
3. Indications andContraindications
Since surgical metastasectomy is the most eﬀective treat-
ment, only patients with unresectable liver disease or who
are unable to undergo surgery should be considered for
embolization procedures. Previous resection of the primary
tumor is not necessary, although the disease should be
stable and not at risk for complications such as bleeding or
obstruction [13].International Journal of Hepatology 3
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Figure 2: Post-TACE MR of bilobar hepatic metastases from the
same patient in the arterial phase. Note the brightness of the aorta
and lack of enhancement of the lesions compared to Figure 1,
indicating the ischemia produced by the embolization.
Liver involvement greater than 75% is considered a rel-
ative contraindication to embolization, since these patients
tend to have less response to treatment coupled with greater
rates of complications [13, 23]. The presence of main
portal vein thrombosis is a strict contraindication since
hepatic arterial embolization relies upon the portal venous
blood supply to rescue the nontumorous liver parenchyma.
Therefore, hepatic arterial embolization in patients with
complete portal vein thrombosis risks severe liver ischemia.
Embolization in patients with bilirubin levels greater
than 2-3mg/dL has also been reported to be unsafe [13, 24,
25]. Even though the liver parenchyma is relatively spared
with arterial embolization, there is nevertheless an ischemic
insult that results in temporary liver insuﬃciency. Patients
with already borderline liver function may be tipped over
into frank liver failure following embolization. Accordingly,
patients with ascites should be carefully considered for
embolization procedures since its presence suggests poor
liver function [13].
Finally, patients with general contraindications to
angiography, intolerance of contrast media, peripheral vas-
cular disease, or coagulopathies should not be considered for
embolization.
4. HepaticArterialEmbolization Technique
Occlusion of the hepatic artery causes selective ischemia to
the tumor, while the remainder of the liver parenchyma is
rescued by the portal venous ﬂow. As a result, the tumor
is disproportionately aﬀected by the ischemic insult, with
relative sparing of the normal parenchyma.
While not curative, hepatic arterial embolization pro-
cedures slow tumor growth and prolong progression-free
survival, until the eventual revascularization from collateral
angiogenesis resupplies the tumor. One lobe of the liver
is treated per session to minimize the risk of liver failure
[25]. If both lobes of the liver are involved with tumor,
the contralateral side can be treated approximately one
month after the initial embolization.
Three types of hepatic arterial embolization techniques
are currently in use: transarterial bland embolization (TAE),
transarterial chemoembolization (TACE), and embolization
using drug-eluting beads (DEB-TACE). These procedures all
involve percutaneous access to the femoral artery, followed
by selective cannulation of the hepatic artery and its
derivatives to the aﬀected lobe. Prior to embolization, an
arteriogram is performed to identify the vascular anatomy
supplying the tumor (Figure 3). If femoral access is not
available, the brachial artery can be used as an alternative,
although this route is more technically challenging.
In bland embolization, catheterization is typically fol-
lowed by the injection of 50µm polyvinyl alcohol (PVA)
particles, with or without ethiodized oil. These particles
physically occludes blood ﬂow through the selected hepatic
artery, thereby inducing ischemic injury; if stasis remains
unachieved, then larger 200–500-µm PVA particles can be
used [26–29]. Other embolic agents currently employed
include gelfoam, cyanoacrylate, tris-acryl particles, and
embospheres [26, 28, 29].
Previous studies established that TAE is eﬀective at
reducing tumor size as well as decreasing tumor hormone
production for palliation of symptoms [11, 25–34]. Systemic
adjuvant chemotherapy following TAE was noted to prolong
the duration of symptom relief, prompting the development
of embolization coupled with chemotherapy [35]. TACE
combines the use of embolic material with an initial infusion
of a chemotherapeutic agent. However, it is unclear whether
the addition of intrahepatic chemotherapy improves the
eﬃcacy of embolization techniques.
The literature has not consistently shown a clear beneﬁt
of TACE over TAE, and no randomized head-to-head studies
have been performed. While select reports have found
that patients treated with TACE experienced slightly longer
progression-free survival (PFS) and greater overall survival
(OS), other reports have not found any beneﬁt of TACE
over TAE [28, 31, 32]. It is likely that the eﬃcacy of these
techniques is largely due to the ischemia produced by the
embolization itself, with only secondary beneﬁts derived
from the addition of chemotherapeutic agents.
In addition, there is no consensus on which chemother-
apeutic agents for TACE are the most eﬃcacious in the
treatment of liver metastases from NETs. Doxorubicin, mito-
mycin C, streptozocin, vinblastine, gemcitabine, ﬂuorouracil
(5-FU), and cisplatin have all been used for TACE, and
some regimens employ them in combination. The most
common regimen described in the literature is a three-drug
combination of doxorubicin (20–30mg), cisplatin (50mg),
and mitomycin C (10–30mg) mixed with 10mL ethiodized
oil [13, 27, 36, 37]. Doxorubicin alone with ethiodized oil
is the second most common regimen described [38–40].
Lipiodol is an oily agent which is typically used during TACE
to enhance chemotherapy retention within the tumor [38].
Lipiodol appears bright white on CT imaging and therefore
interferes with assessment of tumor viability. Surveillance
following TACE should utilize MRI imaging since lipiodol
does not appear on MRI images.4 International Journal of Hepatology
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Figure 3:Arteriogramofthesamepatientwithselectivecatheterizationofthelefthepaticarteryfromthefemoralartery.Carefulpositioning
ofthecatheterisimportanttominimizetheriskofcomplications.Notetheprogressivetumorblushfollowingtheinjectionofcontrastmedia.
A third chemoembolization technique, DEB-TACE, uses
500–700µm embolic beads that are loaded with a chemo-
therapeutic drug, usually doxorubicin, which slowly elutes
intotheliverparenchymaoveraperiodof7–14days[41–43].
The controlled release of chemotherapy allows for sustained,
higher tumor levels of doxorubicin, while maintaining lower
levels in the systemic circulation, which may decrease the
incidence of systemic side eﬀects. Studies have shown the
OS and PFS in patients undergoing chemoembolization with
DEB-TACE to be similar to TAE and TACE [41, 42].
Currently, all three techniques are actively in use, with no
clear evidence for superiority of one approach over another.
5. Outcomes
Although there is a considerable amount of literature on
hepaticarterialembolizationtreatmentsformetastaticNETs,
most are retrospective reviews of smaller case series with
historical controls;there are no randomized controlledtrials.
Due to the rare nature of NETs, prospective studies have
not been feasible. Importantly, all methods of embolization
have greater PFS and OS than no treatment or systemic
chemotherapy alone [6, 11]. Most series include patients
with both metastatic carcinoid tumors as well as pancreatic
islet cell tumors in their cohorts. Patients with carcinoid
NETs in general have longer OS and higher response rates
thanpatientswithpancreaticNETs,andasaresult,outcomes
should be interpreted accordingly [31, 32, 35].
Oneofthelargesttrialstodateontheeﬀectsofemboliza-
tionproceduresisananalysisfromBloomstonandcolleagues
ontheoutcomesofpatientswithmetastaticcarcinoidtumors
undergoing TACE [36]. A cohort of 122 patients underwent
156 TACE procedures using a combination of doxorubicin
(30mg), mitomycin C (30mg), and cisplatin (50mg). The
origin of the primary tumor was predominantly in the small
bowel (47%), pancreas (21%), or lung (8%), with 14% of
unknown origin. 81% of the patients presented with carci-
noid syndrome, and the primary tumor had been previously
resected in 75% of the patients. Interestingly, resection of the
primary tumor did not prove to be predictive of survival.
Following TACE, regression or stabilization of the hepatic
metastases was observed in 94% of the patients, with a
median duration of 19 months. Symptom improvement was
reported in 92% of patients and was associated with a beneﬁt
in OS (41 months versus 8 months). Additionally, a lack of
symptom improvement was associated with lack of radio-
graphic response. PFS for the entire cohort was 10 months,
andOSwasreportedtobe33.3monthswitha5-yearsurvival
of 28% from the date of the ﬁrst TACE procedure [36].
Another large series by Sw¨ ard et al. examined 213 bland
TAE procedures in 107 patients with metastatic carcinoid
tumors. 106 of the patients had resection of the primary
tumor, as well as prophylactic cholecystectomy [33]. Repeat
TAE was performed in the setting of progressive disease,
as demonstrated by two consecutive CT scans at least 6
months apart and a two fold increase in urinary 5-HIAA,
a metabolite of 5-HT. Plasma chromogranin A levels, a
general marker for NETs, were also recorded. Symptomatic
improvement following TAE was reported in 71% of the
patients, and an OS of 56 months from the date of emboliza-
tion was shown for the group. Importantly, Sw¨ ard et al.
were able to demonstrate a relationship between biochemical
markers and survival beneﬁt. Compared to patients who
demonstratednoreductioninurinary5-HIAA,patientswith
greater than 50% reduction experienced a 6-month gain
in estimated survival, with an additional 6-month gain if
the reduction was increased to 75%. In addition, increases
in liver enzymes or chromogranin A both signiﬁcantly
correlated with reduced survival [33].
A more recent study by Pitt et al. compared the outcomes
of100 patients withcarcinoidorisletcelltumorsundergoing
either TACE (n = 49) or TAE (n = 51) [28]. Particle
embolization was performed with PVA, gelfoam, or embo-
spheres; the chemotherapeutic agents used in TACE were
cisplatin, doxorubicin, and mitomycin C. Both cohorts were
similar with respect to age, gender, tumor type, and tumor
burden. 67% of the TACE cohort underwent resection of
the primary tumor, compared with 49% in the TAE cohort,International Journal of Hepatology 5
Table 1: Outcomes of hepatic arterial embolization in large published case series.
Author Type of
embolization
No. of patients/No. of
embolizationprocedures Survival Comments
Bloomston et al. [36] TACE 122/156
PFS: 10 months
OS: 33 months
5-yr survival: 28%
Symptom improvement associated with
increase in OS
Sw¨ ard et al. [33] TAE 107/213 OS: 56 months
Increased survival with reduction in
5-HIAA; reduced survival with increased
AST or chromogranin A
Pitt et al. [28] TACE and TAE 100/229
TACE OS: 25.5
TAE OS: 25.7
TACE 5-yr survival: 19%
TAE 5-yr survival: 13%
OS and 5-yr survival not statistically
diﬀerent between TAE and TACE;
resection of primary tumor increased OS
Kamat et al. [23] TACE and TAE 60/123 OS: 18 months
PFS: 9 months
Patients had greater than 75% hepatic
tumor burden; symptom
improvement seen in 65%; major
complication rate of 29%
Varker et al. [37] Repeat TACE 27/54 OS: 28 months
PFS: 5 months
Repeat TACE associated with similar OS
and PFS, and lower complication rates
compared to single TACE
although this diﬀerence was not signiﬁcant. Response rates
were 86% in the TACE cohort and 83% in patients treated
with TAE and were not statistically diﬀerent. Median overall
survival from the date of the ﬁrst procedure was also similar
between the TACE and TAE groups, at 25.5 months and 25.7
months, respectively. In addition, 5-year survival rates for
the TACE and TAE groups were not statistically diﬀerent at
19% and 13%, respectively. Furthermore, the TACE and TAE
groups exhibited similar complication rates (2.4% versus
6.6%, resp.) and mortality rates (0.8% versus 1.8%, resp.).
In contrast to the study by Bloomston et al., resection of the
primary tumor was signiﬁcantly associated with an increase
in overall survival: 73 months versus 28 months, respectively,
from the time of diagnosis of metastatic disease. No other
factors were found to be signiﬁcantly predictive of survival,
includingtumortype,tumorburden,embolizationtype,and
resection of liver metastases [28].
Patients with extensive liver tumor burden experience
poorer response to embolization, as well as a greater rate
of major complications. A major complication rate of 29%
following embolization has been reported in patients with
large volume disease [23, 31]. However, hepatic arterial
embolization can still be of beneﬁt in this group of patients.
Kamat et al. demonstrated a median overall survival of 17.9
months and a PFS of 9.2 months using either TAE or TACE
in patients with greater than 75% liver involvement. While
only 44% of the patients demonstrated radiologic response,
65% showed improvement of symptoms, indicating that
symptom relief can be used to guide therapy irrespective of
radiologic ﬁndings [23].
6.RepeatedEmbolization
Despite embolization, most patients will exhibit disease
progressionasdeterminedthroughbothradiologicmeasures
and the resumption of symptoms. These patients should
be strongly considered for repeat embolization. Repeat
embolizations are generally spaced 4–6 weeks apart to allow
for the liver to recover fully [33].
The outcomes of patients undergoing repeat TACE have
been reported in the literature, including a study by Varker
et al. [37]. Although both radiologic and symptomatic
responses were found to be slightly lower than for patients
having their initial TACE (61% versus 82% and 77% versus
92%, resp.), this did not reach statistical signiﬁcance. In
addition, OS and PFS were similar between patients having
initial versus repeat TACE. Of note, patients undergoing
repeat embolization better tolerated the procedure and had
a lower complication rate (11% versus 23%) than patients
undergoing initial embolization [37]. These results indicate
t h a tr e p e a tT A C Ei ss a f ea n de ﬀective in patients with
progressive disease after initial embolic therapy and should
be aggressively pursued to maintain disease control. A
summary of the outcomes can be found in Table 1.
7. Complications
Both minor and serious complications as deﬁned by the
Society ofInterventionalRadiology standardcriteria [44]ar e
not uncommon among patients undergoing embolization. A
review of the literature has shown the incidence of serious
complications to range from 3% to 17% in most series
[11, 13, 17, 25–34, 36–38, 45].
Postembolization syndrome (fever, nausea, vomiting,
abdominal pain, and elevated liver enzymes) has been found
to occur in the majority of patients but typically subsides
within three days post-procedurally [11, 16, 27, 29–32,
38, 40]. There are anecdotal reports that the occurrence
of postembolization syndrome correlates with the amount
of tumor insult and that a robust physical response to
embolization is in fact a positive prognostic indicator [46].
Hepatic failure, hepatic abscess, hepatorenal syndrome,
sepsis, and severe hypertension occurring during emboliza-
tion can all result from the local ischemia induced by6 International Journal of Hepatology
arterial embolization [11, 13, 16, 30, 31, 33, 36]. Patients
with bilioenteric anastomoses or large tumors (greater than
5cm) are especially at risk for hepatic abscess formation
after embolization [47, 48]. Due to the risk of abscess
formation, many physicians advise prophylactic antibiotic
administration prior to the procedure [25, 27, 29, 36, 38].
Patients who develop a hepatic abscess can be treated with
percutaneous drain placement and parenteral antibiotics;
rarely liver resection may be indicated for persistence [30].
Cholecystitis and pancreatitis are both relatively com-
mon complications of hepatic arterial embolization. These
events are thought to be due to reﬂux of embolic mate-
rial into the cystic artery or pancreaticoduodenal artery
respectively, causing ischemic injury to these organs. Careful
positioning of the catheter tip into the intrahepatic portion
of the hepatic artery, along with gentle infusion techniques,
is thought to limit the incidence of these potentially serious
complications [24].
Mortality following embolization procedures is rare in
high-volume centers. In a study of 26 patients undergoing 62
TACE procedures, Kress et al. reported fatal hepatic failure
in 2 patients (3.2%) within 30 days after embolization [38].
Similar 30-day mortality rates have been found by other
investigators, ranging from 0% to 6%, the majority of which
were caused by hepatic failure, acute renal failure, sepsis, and
myocardial infarction [17, 27, 30, 31, 36].
As to be expected, both acute and chronic renal failure
secondary to contrast media administration during arteri-
ogram have been noted as a severe complication from TAE
and TACE [23, 27, 38]. Finally, all hepatic arterial emboliza-
tion procedures carry the potential complications which
accompany femoral arterial catheterization, including groin
hematoma, peripheral embolization, and arterial dissection
[27, 30, 33].
Of note, patients having TAE have similar rates of com-
plication compared to patients having TACE [28]. Addition-
ally, DEB-TACE procedures have demonstrated comparable
morbidity rates, with 30%–60% of patients experiencing ele-
ments of postembolization syndrome [42]. Both Gaur et al.
and de Baere et al. reported mortality rates of 5% in patients
undergoing DEB-TACE [41, 42]. Table 2 summarizes the
characteristics of hepatic arterial embolization.
8. Conclusion
Patients with NETs metastatic to the liver are often aﬄicted
with debilitating symptoms that severely aﬀect quality of life,
andmostpatientswithNETsultimatelydiefromprogression
in the liver. As a result, control of the hepatic tumor burden
should be the primary goal in the management of patients
with metastatic NETs. Surgical metastasectomy is considered
preferable, although there are no randomized controlled
trials comparing resection to nonsurgical therapies. In cases
where resection is not feasible, interventional radiologic
therapies such as hepatic arterial embolization can be used
to control disease progression. The characteristic arterial
enhancement of NETs can be taken advantage of, allowing
selective embolization of the tumor while sparing normal
parenchyma. Several modalities and chemotherapy regimens
Table 2: Characteristics of hepatic arterial embolization for NET
metastases.
Indications
Hepatic metastases of NET
Nonoperative candidates
Symptomatic and asymptomatic tumors
Contraindications
Main portal vein thrombosis
Bilirubin greater than 2-3mg/dL
Hepatic tumor burden greater than 75%
Contraindications to angiography
Outcomes
Mortality 0–6%
Median OS 25–56 months
5-yr survival 13–28%
Common chemotherapeutic agents
None (bland embolization)
Doxorubicin
Mitomycin C
Cisplatin
Most frequent complications
Postembolization syndrome
Hepatic abscess
Hepatic failure
Cholecystitis
Pancreatitis
Indications for repeat embolization
Increase in tumor size or tumor enhancement
Progression of symptoms
exist, and all have proven eﬃcacy. Although not curative,
hepatic arterial embolization can improve symptoms and
reduce or stabilize tumor progression, prolonging PFS and
OS, and should be the mainstay of treatment of patients
with liver metastases from NETs. Embolizations should be
repeated as needed to control symptoms and slow tumor
growth.
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